Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company Dec 18, 2025
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser Sep 16, 2025
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray Sep 10, 2025
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference Sep 4, 2025
